Hong Kong King-Friend Industrial Company Limited announced that it will receive $21 million in an equity round of funding from returning investor Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd on July 14, 2022. On closing, the investor retains its 100% stake in the company. The transaction has been approved by board of directors of investor in its fifteenth Meeting of the fourth Board of Directors.
Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd.
Equities
603707
CNE100002WP3
Pharmaceuticals
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
13.81 CNY | +2.60% | -0.65% | -7.93% |
05-13 | NKFPharma's Unit Gets FDA's Nod to Market Eptifibatide Injection in US | MT |
05-01 | NKFPharma Gets Nod to Register New Cancer Treatment | MT |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-7.93% | 3.08B | |
+32.09% | 693B | |
+29.39% | 584B | |
-1.34% | 372B | |
+20.34% | 332B | |
+7.39% | 294B | |
+13.83% | 239B | |
-3.03% | 211B | |
+10.02% | 210B | |
+8.49% | 168B |
- Stock Market
- Equities
- 603707 Stock
- News Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd.
- Hong Kong King-Friend Industrial Company Limited announced that it expects to receive $21 million in funding from Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd